Jb Capital LLC Bristol Myers Squibb CO Transaction History

Jb Capital LLC

$1.58 Billion
Q2 2024

A detailed history of Jb Capital LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Jb Capital LLC holds 5,700 shares of BMY stock, worth $303,183. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,700

Previous 5,740 0.7%

Holding current value

$303,183

Previous $311,000 24.12%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 24, 2024	SELL	$40.25 - $52.99 $1,610 - $2,119	-40 Reduced 0.7%	5,700 $236,000
Q1 2024 Apr 30, 2024	SELL	$47.98 - $54.4 $55,896 - $63,376	-1,165 Reduced 16.87%	5,740 $311,000
Q4 2023 Jan 22, 2024	BUY	$48.48 - $57.85 $6,787 - $8,099	140 Added 2.07%	6,905 $354,000
Q3 2023 Oct 25, 2023	SELL	$57.89 - $64.73 $6,657 - $7,443	-115 Reduced 1.67%	6,765 $392,000
Q2 2023 Jul 25, 2023	SELL	$63.71 - $70.74 $4,905 - $5,446	-77 Reduced 1.11%	6,880 $439,000
Q1 2023 Apr 25, 2023	BUY	$65.71 - $74.53 $28,518 - $32,346	434 Added 6.65%	6,957 $482,000
Q4 2022 Jan 23, 2023	BUY	$68.48 - $81.09 $1,985 - $2,351	29 Added 0.45%	6,523 $0
Q3 2022 Oct 14, 2022	SELL	$0.13 - $76.84 $33 - $19,824	-258 Reduced 3.82%	6,494 $462,000
Q2 2022 Jul 28, 2022	BUY	$72.62 - $79.98 $1,960 - $2,159	27 Added 0.4%	6,752 $520,000
Q1 2022 Apr 19, 2022	BUY	$61.48 - $73.72 $21,579 - $25,875	351 Added 5.51%	6,725 $492,000
Q4 2021 Feb 02, 2022	SELL	$53.63 - $62.52 $16,196 - $18,881	-302 Reduced 4.52%	6,374 $397,000
Q3 2021 Dec 08, 2021	BUY	$59.17 - $69.31 $395,018 - $462,713	6,676 New	6,676 $395,000

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jb Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jb Capital LLC with notifications on news.

Account